Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Ovarian Cancer Antibodies

Epithelial epithelial ovarian cancer accounts for approximately 95% of cases. This cancer exhibits diverse histological subtypes like serous, endometrioid, and clear cell carcinomas, each with unique characteristics and clinical implications. Techniques including Western blots, ELISA, flow cytometry, co-immunoprecipitation, and immunohistochemistry can provide vital information about cell proliferation and disease progression, which is critical for the early detection, prognosis/monitoring, and treatment of the disease.

NeoBiotechnologies proudly offers a comprehensive selection of antibodies for ovarian cancer research (see the table below), with a particular emphasis on IHC-validated antibodies. Our antibodies targeting ovarian cancer protein markers are rigorously validated for specificity, ensuring precise and reliable results.

Notable ovarian cancer markers:

  • CA-125 (Cancer Antigen 125): one of the most well-known biomarkers for ovarian cancer. It is elevated in the blood of many ovarian cancer patients and is used for monitoring response to treatment and disease recurrence.
  • HE4 (Human Epididymis Protein 4): a protein often elevated in the blood of ovarian cancer patients. It can be used in combination with CA-125 to improve the sensitivity and specificity of ovarian cancer diagnosis.
  • p53: Mutations and abnormal expression of the p53 tumor suppressor gene are common in high-grade serous ovarian cancer and can influence prognosis and treatment options.
  • BRCA1 and BRCA2: Mutations in the BRCA1 and BRCA2 genes are associated with an increased risk of ovarian cancer. Testing for these mutations helps identify high-risk individuals and can guide preventive measures.
  • ER (Estrogen Receptor): ER expression is used to diagnose borderline and low-grade serous ovarian cancers. Hormone therapy may be considered in some cases.
  • PR (Progesterone Receptor): expression is also used to diagnose borderline and low-grade serous ovarian cancers.
  • ERBB2 (Human Epidermal Growth Factor Receptor 2): Overexpression or amplification of ERBB2 (HER2) is found in a subset of ovarian cancers and may be targetable with anti-HER2 therapies.
  • CA-72-4: a tumor marker that can be elevated in certain types of ovarian cancer.
  • CEA (Carcinoembryonic Antigen): levels can be elevated in ovarian cancer, and it is used for monitoring treatment response and disease recurrence.
  • Vimentin: an intermediate filament protein often expressed in ovarian cancer cells and can be used in immunohistochemistry for diagnosis.
  • Inhibin: a marker for granulosa cell tumors, a rare subtype of ovarian cancer.
  • Calretinin: used in IHC to identify specific subtypes of ovarian cancer, such as mesothelioma and sex cord-stromal tumors.
  • Alpha-fetoprotein (AFP): a marker for certain germ cell tumors, which are a distinct subtype of ovarian cancer.

Showing 1–25 of 197 results

Ovarian Cancer

Showing 1–25 of 197 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.